Prednisone : interactions médicamenteuses

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (notice Abiratérone, Mises en garde et précautions)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Adalimumab, Mise en garde encadrée)

…Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (notice Adrénaline, Interactions médicamenteuses)

Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (notice Arformotérol, Contre-indications)

Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (notice Atazanavir, Interactions médicamenteuses)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (notice Axitinib, Mises en garde et précautions)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Baricitinib, Mise en garde encadrée)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (notice Emtricitabine, rilpivirine et ténofovir, Contre-indications)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Étanercept, Mise en garde encadrée)

Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (notice Formotérol, Contre-indications)

Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (notice Fosamprénavir, Interactions médicamenteuses)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Infliximab, Mise en garde encadrée)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (notice Kétoconazole, Interactions médicamenteuses)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (notice Lovastatine, Contre-indications)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (notice Mifépristone, Mise en garde encadrée)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (notice Mitotane, Mise en garde encadrée)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (notice Moexipril, Mises en garde)

Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended. (notice Névirapine, Mises en garde et précautions)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (notice Rilpivirine, Contre-indications)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (notice Salmétérol, Mise en garde encadrée)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (notice Sirolimus, Mises en garde et précautions)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (notice Somatropine, Interactions médicamenteuses)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Tocilizumab, Mise en garde encadrée)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Tofacitinib, Mise en garde encadrée)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (notice Trandolapril, Mises en garde)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (notice Trioxyde d'arsenic, Mise en garde encadrée)

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (notice Uméclidinium et vilantérol, Contre-indications)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (notice Upadacitinib, Mise en garde encadrée)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide alendronique, Mises en garde et précautions)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide ibandronique, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (notice Acide pamidronique, Mises en garde et précautions)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (notice Acide risédronique, Mises en garde et précautions)

Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (notice Acide valproïque, Interactions médicamenteuses)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (notice Acide zolédronique, Mises en garde et précautions)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (notice Aclidinium, Interactions médicamenteuses)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (notice Afatinib, Mises en garde et précautions)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (notice Albendazole, Mises en garde et précautions)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (notice Alemtuzumab, Mises en garde et précautions)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (notice Aliskirène, Mises en garde et précautions)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (notice Amphotéricine B, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. (notice Azathioprine, Mises en garde)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Hypercorticism and Adrenal Suppression QVAR REDIHALER will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (notice Béclométasone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Belladone et opium, Mises en garde et précautions)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (notice Bendamustine, Mises en garde et précautions)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (notice Benralizumab, Mises en garde et précautions)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with PULMICORT FLEXHALER. (notice Budésonide, Mises en garde et précautions)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (notice Budésonide et formotérol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine et naloxone, Mises en garde et précautions)

…risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (notice Bupropion, Mises en garde et précautions)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Butorphanol, Mises en garde)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (notice Céfoxitine, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during ALVESCO therapy [see Dosage and Administration ( 2 )] . (notice Ciclésonide, Mises en garde et précautions)

Cyclosporine: Increase in activity of both, cyclosporine and corticosteroid when administered concurrently. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ciprofloxacine, Mises en garde et précautions)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (notice Cladribine, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (notice Cocaïne, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Codéine, Mises en garde et précautions)

Cholestyramine Cholestyramine may increase the clearance of corticosteroids. (notice Prednisone, Interactions médicamenteuses)

Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (notice Cytarabine, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (notice Daptomycine, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (notice Dénosumab, Mises en garde et précautions)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (notice Dicyclovérine, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Digitalis Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

…following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (notice Dolutégravir, Interactions médicamenteuses)

…treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase. (notice Doxorubicine, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (notice Dupilumab, Mises en garde et précautions)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (notice Élexacaftor, tézacaftor et ivacaftor, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (notice Prednisone, Interactions médicamenteuses)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (notice Erlotinib, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Fentanyl, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (notice Fingolimod, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

The use of flunisolide with alternate-day prednisone systemic treatment could increase the likelihood of HPA suppression compared to a therapeutic dose of either one alone. (notice Flunisolide, Mises en garde)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with Fluticasone Propionate DISKUS. (notice Fluticasone, Mises en garde et précautions)

Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of Fluticasone Propionate/Salmeterol MDPI, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (notice Fluticasone et salmétérol, Mises en garde et précautions)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (notice Halobétasol, Mises en garde et précautions)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (notice Halopéridol, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (notice Hydralazine, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et chlorphénamine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et homatropine, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et paracétamol, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydromorphone, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antitubercular Drugs Serum concentrations of isoniazid may be decreased. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (notice Ivermectine, Mises en garde)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Lévofloxacine, Mises en garde et précautions)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Lévorphanol, Mises en garde)

If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Lévosalbutamol, Mises en garde et précautions)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (notice Prednisone, Mises en garde et précautions)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (notice Prednisone, Mises en garde et précautions)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (notice Prednisone, Mises en garde et précautions)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (notice Lisinopril et hydrochlorothiazide, Mises en garde)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (notice Margétuximab, Mises en garde et précautions)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Decrease corticosteroids gradually, if appropriate. (notice Mépolizumab, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Méthadone, Mises en garde et précautions)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (notice Méthazolamide, Interactions médicamenteuses)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (notice Prednisone, Interactions médicamenteuses)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (notice Méthotrexate, Interactions médicamenteuses)

If not, corticosteroids may be given and other causes of anemia should be considered. (notice Méthyldopa, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (notice Métolazone, Interactions médicamenteuses)

This can be corrected by giving appropriate doses of corticosteroids. (notice Métyrapone, Mises en garde et précautions)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (notice Mitoxantrone, Mises en garde)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Hypercorticism and Adrenal Suppression ASMANEX HFA will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (notice Mométasone, Mises en garde et précautions)

Inhaled corticosteroid may be reduced gradually. (notice Montélukast, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Morphine, Mises en garde et précautions)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Moxifloxacine, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Nalbuphine, Mises en garde)

…hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (notice Naltrexone et bupropion, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (notice Natalizumab, Mises en garde et précautions)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (notice Ocrélizumab, Mises en garde et précautions)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ofloxacine, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Olicéridine, Mises en garde et précautions)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (notice Omalizumab, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone et paracétamol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxymorphone, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Paracétamol et codéine, Mises en garde)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (notice Pasiréotide, Mises en garde et précautions)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (notice Pénicillamine, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Pentazocine et naloxone, Mises en garde)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Péthidine, Mises en garde et précautions)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de glycérol, Interactions médicamenteuses)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de sodium, Interactions médicamenteuses)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (notice Phényléphrine, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (notice Ponésimod, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. (notice Prednisone, Mises en garde et précautions)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (notice Prednisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Prométhazine et codéine, Mises en garde et précautions)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (notice Propofol, Mises en garde et précautions)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (notice Prednisone, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (notice Rocuronium, Mises en garde et précautions)

If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Salbutamol, Mises en garde et précautions)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (notice Suxaméthonium, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. (notice Tacrolimus, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tapentadol, Mises en garde et précautions)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (notice Témozolomide, Mises en garde et précautions)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (notice Temsirolimus, Mises en garde et précautions)

If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Terbutaline, Mises en garde)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (notice Prednisone, Mises en garde et précautions)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (notice Testostérone, Mises en garde et précautions)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (notice Théophylline, Mises en garde)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (notice Prednisone, Mises en garde et précautions)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (notice Tiotropium, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (notice Prednisone, Interactions médicamenteuses)

Corticosteroids and ACTH: Increased risk of hypokalemia. (notice Torasémide, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol et paracétamol, Mises en garde et précautions)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (notice Triamtérène et hydrochlorothiazide, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (notice Prednisone, Interactions médicamenteuses)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (notice Prednisone, Interactions médicamenteuses)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (notice Zénocutuzumab, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (notice Acide bempédoïque, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (notice Altéplase, Mises en garde et précautions)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (notice Amikacine, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Amphétamine, Interactions médicamenteuses)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Amphétamine et dexamfétamine, Interactions médicamenteuses)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Ampicilline, Mises en garde)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (notice Bévacizumab, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

…50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin,… (notice Bortézomib, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (notice Busulfan, Mises en garde)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (notice Calcitriol, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (notice Cannabidiol (sur ordonnance), Mises en garde et précautions)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfaclor, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfadroxil, Mises en garde et précautions)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefdinir, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfotétan, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefprozil, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Ceftazidime, Mises en garde)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (notice Ceftriaxone, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (notice Clofarabine, Mises en garde et précautions)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (notice Clomifène, Mises en garde)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (notice Corticotropine, Mises en garde et précautions)

Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (notice Cyclosilicate de zirconium sodique, Interactions médicamenteuses)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Dexamfétamine, Interactions médicamenteuses)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (notice Dropéridol, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Steroids may or may not be effective in controlling these hemolytic episodes. (notice Fludarabine, Mises en garde et précautions)

Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (notice Prednisone, Mises en garde et précautions)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (notice Fluoxétine, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (notice Glucagon, Mises en garde et précautions)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (notice Guselkumab, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Amphotericin B Injection There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure [see Drug Interactions (7.14) ] . (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (notice Lénalidomide, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (notice Melphalan, Mises en garde)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Méthamphétamine, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (notice Midodrine, Interactions médicamenteuses)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (notice Naltrexone, Mises en garde et précautions)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

Moderate and weak CYP3A4 inducers include, for example: amprenavir, aprepitant, armodafinil, bosentan, efavirnenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib. (notice Nimodipine, Interactions médicamenteuses)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (notice Olanzapine et fluoxétine, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (notice Oxacilline, Mises en garde)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (notice Pénicilline G, Mises en garde)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Pénicilline V, Mises en garde)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (notice Pilocarpine, Interactions médicamenteuses)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (notice Quinine, Interactions médicamenteuses)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (notice Raloxifène, Interactions médicamenteuses)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (notice Rituximab, Mises en garde et précautions)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (notice Ténectéplase, Mises en garde et précautions)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (notice Ustékinumab, Mises en garde et précautions)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (notice Prednisone, Interactions médicamenteuses)

Les corticoïdes tels que la prednisone réduisent l'absorption du calcium et perturbent le métabolisme de la vitamine D, ce qui contribue à la perte osseuse. (NIH Office of Dietary Supplements, Vitamin D)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (notice Ziprasidone, Mises en garde et précautions)

…influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline… (notice Aminophylline, Interactions médicamenteuses)

Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (notice Zileuton, Interactions médicamenteuses)